**Supplementary Figure 1:** Box-plots/Stacked bars of incidence of MACE according to LVEF, age, FMD and tertiles of galectin-3; **Panel A:** Incidence of MACE according to LVEF; **Panel B:** Incidence of MACE according to age; **Panel C:** Incidence of MACE according to FMD; **Panel D:** Incidence of MACE according to tertiles of galectin-3. LVEF: left ventricular ejection fraction; FMD: flow-mediated dilatation; MACE: major adverse cardiovascular events

**Supplementary Figure 2:** ROC curve of the prognostic capability of LVEF category, FMD and galectin-3 (highest tertile) for MACE; **Panel A:** ROC curve of the prognostic capability of LVEF category for MACE; **Panel B:** ROC curve of the prognostic capability of FMD for MACE, **Panel C:** ROC curve of the prognostic capability of galectin-3 (highest tertile) for MACE. LVEF: left ventricular ejection fraction; FMD: flow-mediated dilatation; MACE: major adverse cardiovascular events; ROC curve: Receiver Operating Characteristic curve

**Supplementary Figure 3.** ROC curve of the prognostic capability of LVEF category, FMD and galectin-3 (highest tertile) for the combined end point of rehospitalization for HF and/or death. **Panel A:** ROC curve of the prognostic capability of LVEF for the combined end point of rehospitalization for HF and/or death; **Panel B:** ROC curve of the prognostic capability of FMD for the combined end point of rehospitalization for HF and/or death; **Panel C:** ROC curve of the prognostic capability of the highest tertile of galectin-3 for the combined end point of rehospitalization for HF and/or death. LVEF: left ventricular ejection fraction; FMD: flow-mediated dilatation; HF: heart failure; ROC curve: Receiver Operating Characteristic curve